18F-FDG PET/CT imaging is an important diagnostic tool for accurate staging and assessment of response to neoadjuvant chemotherapy (NACT) in patients with locally advanced breast carcinoma (LABC). However, 18F-FDG being non-specific marker, it also accumulates in inflammatory conditions, leading to false positive results. Angiogenesis, an essential characteristic for tumor development, intrusion and metastasis can be imaged using 68Ga-labeled RGD tripeptide. We here depict a series of clinically staged LABC patients who underwent both 68Ga-DOTA-RGD2 and 18F-FDG PET/CT imaging for staging and illustrate the similarities and significant differences between the two tracers.
From the *Department of Nuclear Medicine,
†General Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Received for publication January 14, 2019; revision accepted April 22, 2019.
Conflicts of interest and sources of fundings: none declared.
Correspondence to: Bhagwant Rai Mittal, Department of Nuclear Medicine and PET, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India. E-mail: firstname.lastname@example.org.
Online date: June 3, 2019